Zoetis™ Prices Initial Public Offering

  Zoetis™ Prices Initial Public Offering

Business Wire

MADISON, N.J. -- January 31, 2013

Zoetis^TM, formerly the animal health business unit of Pfizer Inc., today
announced the pricing of its initial public offering of 86,100,000 shares of
its Class A common stock at $26 per share. The shares are expected to begin
trading tomorrow, Feb.1, on the New York Stock Exchange under the symbol

Zoetis will not receive any of the proceeds of the offering. Following the
completion of the initial public offering, Pfizer will own 100% of the
outstanding Class B common stock of Zoetis and will retain an approximately 83
percent ownership of Zoetis.

The underwriters also have an option to purchase up to an additional
12,915,000 shares of Class A common stock. Zoetis will not receive any of the
proceeds from any shares sold pursuant to this option. If the underwriters
exercise this option in full, Pfizer is expected to retain an approximately 80
percent ownership of Zoetis.

J.P. Morgan, BofA Merrill Lynch and Morgan Stanley served as joint lead
book-running managers for the offering. Barclays, Citigroup, Credit Suisse,
Deutsche Bank Securities, Goldman, Sachs & Co., Guggenheim Securities and
Jefferies served as book-running managers for the offering. BNP PARIBAS, HSBC,
Loop Capital Markets, RBC Capital Markets, The Williams Capital Group, L.P.
and UBS Investment Bank served as senior co-managers for the offering.
Lebenthal Capital Markets, Piper Jaffray and Ramirez & Co., Inc. served as
co-managers for the offering.

The offering is being made only by means of a prospectus. A copy of the final
prospectus related to the offering will be filed with the Securities and
Exchange Commission, which may be obtained, when available, from J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; BofA Merrill Lynch,
Attention: Prospectus Department, 222 Broadway, New York, NY 10038, email:
dg.prospectus_requests@baml.com; Morgan Stanley & Co. LLC, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014,
email: prospectus@morganstanley.com, telephone: (866) 718-1649.

A registration statement relating to these securities has been filed with and
declared effective by the Securities and Exchange Commission. This press
release shall not constitute an offer to sell or the solicitation of an offer
to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any state or

About Zoetis

Zoetis (zō-EH-tis) is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on a 60-year history
as the animal health business of Pfizer, Zoetis discovers, develops,
manufactures and markets veterinary vaccines and medicines, with a focus on
both farm and companion animals. The company generated annual revenue of $4.2
billion in fiscal 2011. Zoetis has more than 9,500 employees and a local
presence in approximately 70 countries, including 29 manufacturing facilities
in 11 countries. Its products serve veterinarians, livestock producers and
people who raise and care for farm and companion animals in 120 countries.

DISCLOSURE NOTICE: This news release contains forward-looking statements,
which reflect Zoetis’ current views with respect to business plans or
prospects, future operating or financial performance, and other future events.
These statements are not guarantees of future performance. Forward-looking
statements are subject to risks and uncertainties. If one or more of these
risks or uncertainties materialize, or if management's underlying assumptions
prove to be incorrect, actual results may differ materially from those
contemplated by a forward-looking statement. Forward-looking statements speak
only as of the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise. A further list and
description of these risks, uncertainties and other factors can be found in
Zoetis’ Registration Statement on Form S-1 (File No. 333-183254), as amended,
filed with the Securities and Exchange Commission. This filing and subsequent
filings are available online at www.sec.gov or on request from Zoetis.


Bill Price, 1-973-660-5763
Elinore White, 1-973-401-4044
Dina Fede, 1-973-660-5441
John O’Connor, 1-973-660-6964
Press spacebar to pause and continue. Press esc to stop.